Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 3/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16401811 | 0.78 | ALDH1A1 (0.46) | CYP1A2KDM4EGAACYP2A6NPC1 | |
| SCHEMBL3785401 | 0.78 | TAAR1 (0.46) | CYP1A2KDM4ELMNAGAANPC1 | |
| SCHEMBL5539585 | 0.78 | NPC1 (0.39) | NOTUMKDM4ELMNAL3MBTL1NPC1 | |
| SCHEMBL5539417 | 0.78 | PTGS1 (0.38) | NOTUMNPC1RAB9ATP53HSD17B10 | |
| SCHEMBL1479814 | 0.78 | NOTUM (0.47) | CYP1A2NOTUMNPC1RAB9ATP53 | |
| SCHEMBL5537658 | 0.74 | NOTUM (0.34) | CYP1A2NOTUMNPC1RAB9A | |
| SCHEMBL3789941 | 0.74 | TAAR1 (0.52) | KDM4ECYP2A6NPC1ALDH1A1TP53 | |
| SCHEMBL5534498 | 0.74 | KIF11 (0.52) | CYP1A2NOTUMCYP2A6NPC1ALDH1A1 | |
| SCHEMBL25036 | 0.73 | — | — | |
| SCHEMBL5536624 | 0.71 | POLB (0.45) | NOTUMLMNAGAAL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6083945-A | USEFUL IN TREATING HUMANS OR OTHER MAMMALS WITH CARDIAC ARRHYTHMIA AND/OR CARDIAC FIBRILLATION | THE PROCTER & GAMBLE COMPANY (US) | 2000-07-04 | — | — | US | claimed |
| US-5691369-A | CARDIOVASCULAR DISORDERS | THE PROCTOR & GAMBLE COMPANY (US) | 1997-11-25 | — | — | US | claimed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| US-8586770-B2 | Unsaturated steroid compounds | Harbor Therapeutics, Inc. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20120029260-A1 | Screening and Treatment Method | BIOVIE INC. | 2012-02-02 | — | — | US | disclosed |
| US-20110137057-A1 | Unsaturated Steroid Compounds | BIOVIE INC. | 2011-06-09 | — | — | US | disclosed |
| US-20110085984-A1 | Drug Product and Process for Making | BIOVIE INC. | 2011-04-14 | — | — | US | disclosed |
| US-7915280-B2 | Compounds and their uses | EISAI INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-7910755-B2 | Stem cell expansion and uses | HARBOR BIOSCIENCES, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| EP-0891976-A1 | Novel cyclic ureas useful as antiarrhythmic and antifibrillatory agents | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1999-01-20 | — | — | EP | disclosed |
| US-5691369-A | CARDIOVASCULAR DISORDERS | THE PROCTOR & GAMBLE COMPANY (US) | 1997-11-25 | — | — | US | disclosed |
| US-5462940-A | 4-oxocyclic ureas useful as antiarrhythmic and antifibrillatory agents | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1995-10-31 | — | — | US | disclosed |
| EP-0599968-A1 | CYCLIC URETHANES USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1994-06-08 | — | — | EP | disclosed |
| EP-0598046-A1 | NOVEL CYCLIC UREAS USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1994-05-25 | — | — | EP | disclosed |
| EP-0598061-A1 | NOVEL 4-OXOCYCLIC UREAS USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1994-05-25 | — | — | EP | disclosed |
| WO-1993004064-A1 | CYCLIC URETHANES USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1993-03-04 | — | — | WO | disclosed |
| WO-1993004061-A1 | NOVEL 4-OXOCYCLIC UREAS USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1993-03-04 | — | — | WO | disclosed |
| WO-1993004060-A1 | NOVEL CYCLIC UREAS USEFUL AS ANTIARRHYTHMIC AND ANTIFIBRILLATORY AGENTS | PROCTER & GAMBLE PHARMACEUTICALS (US) | 1993-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110085984-A1 | Drug Product and Process for Making | CYP2D6, CYP3A5, CYP2B6 | CYP1A2 11/4885NOTUM 1283/4885KDM4E 1510/4885 |
| US-20110137057-A1 | Unsaturated Steroid Compounds | SREBF1, SREBF2, NR1H3 | CYP1A2 1144/4885NOTUM 1047/4885KDM4E 3539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.